Table 3 Outcome
Characteristics | n = 41 localized tumors |
|---|---|
Follow-up (month) | |
Median | 59 |
min | 2.4 |
max | 186 |
Prognosis | |
Death | 9 |
Local relapse | 20 (49%) |
Metastases | 8 |
Local relapse | |
In the « non imatinib treatment group » | 18 (72%) |
In the « imatinib treatment group » | 2 (16%) |
6/11 patients (54.5%) who underwent abdominoperineal resection (exclusively in « non IM group) | |
Metastases | |
In the « non imatinib treatment group » | 6 |
In the « imatinib treatment group » | 2 |
Local relapse-free survival at 3 years | 60.2% [CI95% = 45.8-79.1] |
Local relapse-free survival at 5 years | 42.1% [CI95% = 26.8-66.3] |
DFS at 3 years | 53.9% [CI95% = 39.3-73.8%] |
DFS at 5 years | 34.6% [CI95% = 19.9-60.2%] |
OS at 3 years | 97.5% [CI95% = 92.8-100%] |
OS at 5 years | 86.5% [CI95% = 74.9-100%] |